CIRM Funded Clinical Trials

Allogeneic Cardiac-Derived Stem Cells for Patients Following a Myocardial Infarction


Rachel Smith
Disease Area: 
Investigator:
Institution:
CIRM Grant:
Award Value:
$19,782,136
Trial Sponsor:
Trial Stage: 
Phase 2
Trial Status: 
Active, not recruiting
Targeted Enrollment:
134
ClinicalTrials.gov ID:
Details: 

Heart failure is a progressive disease with a high risk of mortality. Cardiosphere-derived cells (CDCs) reduce scar size after heart attack in preclinical animal models and in a prior clinical trial.

Design: 

Randomized, double-blind placebo-controlled. Intra-coronary delivery, single dose.

Goal: 

Primary: Determine whether treatment is safe and causes reduction in cardiac scar size in patients with heart failure after a heart attack. Secondary: Assess for other structural or functional cardiac benefits.

Status: 

This study is ongoing, but not recruiting participants.